A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

NCT07458347 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

145

Enrollment

OTHER

Sponsor class

Conditions

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
KRAS-mutant Colorectal Cancer (CRC)
Other KRAS-mutant Solid Tumors

Interventions

DRUG: KST-6051

Sponsor

Kestrel Therapeutics, Inc.